Browsing Tag
Ovarian Cancer
32 posts
Gilead Sciences (GILD) is buying Tubulis after Arcellx and Ouro. How aggressive is this deal spree getting?
Gilead is acquiring Tubulis for up to $5 billion to expand its ADC pipeline. Read what the deal means for oncology strategy, risk, and GILD stock.
Why Cyclin E1 biomarker targeting may become central to next-generation ovarian cancer therapies
Find out why Zentalis Pharmaceuticals’ Cyclin E1 strategy could reshape ovarian cancer treatment and investor sentiment into 2026.
Corcept Therapeutics (CORT) stock in focus as ROSELLA survival data strengthen Lifyorli launch in ovarian cancer
Corcept Therapeutics strengthened its Lifyorli launch with new ROSELLA survival data. Read what this means for CORT stock and ovarian cancer treatment.
Why the IMNN-001 and PARP inhibitor pairing could matter more than the standalone data in ovarian cancer
IMNN-001 plus PARP inhibitors shows extended survival in ovarian cancer. Find out what this means for IMUNON Inc. and future treatment strategies.
FDA approval positions MyChoice CDx as key HRD test for ovarian cancer therapy selection
Myriad Genetics secures FDA approval for MyChoice CDx with Zejula. Discover how this reshapes oncology diagnostics and precision medicine markets.
What the LYMPHIR–pembrolizumab combination signals for the future of immunotherapy resistance (NASDAQ: CTOR)
Citius Oncology reports LYMPHIR immunotherapy data in gynecologic cancers. Discover what the trial signals for the future of cancer immunotherapy.
KEYNOTE-B96 final analysis: Merck’s Keytruda cuts death risk by 18% in recurrent ovarian cancer across all-comer population
Merck's Keytruda cuts death risk 18% in platinum-resistant ovarian cancer regardless of PD-L1 status. FDA approved, EU opinion positive. Read the full analysis.
Eli Lilly’s sofetabart mipitecan earns FDA Breakthrough Therapy status in platinum-resistant ovarian cancer
Eli Lilly's sofetabart mipitecan receives FDA Breakthrough Therapy designation in platinum-resistant ovarian cancer. Find out what this means for the ADC space.
Is Ernexa Therapeutics (NASDAQ: ERNA) turning into the next small‑cap biotech breakout?
Is Ernexa Therapeutics (NASDAQ: ERNA) the next small-cap biotech breakout? Learn how its iMSC platform and Cellipont partnership could change its trajectory.
Ernexa’s ERNA-101 cell therapy takes major step toward clinical trials through Cellipont manufacturing deal
Discover how Ernexa Therapeutics and Cellipont Bioservices are teaming up to manufacture ERNA-101 for ovarian cancer, marking a milestone in allogeneic cell therapy.